Tumor Mutational Burden and Response Rate to PD-1 Inhibition
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
In a survey of the spectrum of mutational burdens in 27 types of cancers, there was a correlation between an increased mutational burden and the response to checkpoint inhibition of PD-1 and PD-L1.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, these studies are limited to particular cancer types and subsets of patients, due to difference in mutation load seen in different cancer types, and immune-related adverse effects of therapy may occur [93][94][95][96].”
From Cancer-on-chip models for metastasis: importance of the tumor microenvironment (2024) · cites this paper as [93]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While these markers have clinical utility in specific contexts, their predictive accuracy varies considerably across tumor histologies and patient populations.”
From PathTIGR: A pathway topology-informed graph representation learning framework for immunotherapy response prediction (2026) · doi:10.1126/sciadv.aed6373 · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While high TMB and immune checkpoint molecule expression, including PD-L1, have been used as predictive biomarkers across different cancer types, they have limited clinical utility when considered in isolation88,101.”
From Multi-omic analysis of hepatocellular carcinoma reveals aberrant cis-regulatory changes and dysregulated retrotransposons with prognostic potential (2025) · cites this paper as [88]
Experimental — accuracy not yet measuredIn the citing paper
“Although high TMB led to FDA approval, it should be noted that certain tumor types with moderate TMB carry relatively high response rates to ICT, such as clear cell RCC (128, 129).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [128]
In the citing paper
“Melanoma, lung, and bladder cancer, tumors commonly associated with an increased number of mutations due to environmental DNA damage, exhibit a stronger response to ICB (Yarchoan et al., 2017).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Yarchoan et al., 2017
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
Chalmers, Z. R., Connelly, C. F., Fabrizio, D., Gay, L., Ali, S. M., Ennis, R., Schrock, A., Campbell, B., Shlien, A., Chmielecki, J., et al. (2017) · Genome Medicine · doi:10.1186/s13073-017-0424-2 · Cited by 3,519
PD-1 Blockade with pembrolizumab in advanced Merkel-cell carcinoma
Nghiem, P. T., Bhatia, S., Lipson, E. J., Kudchadkar, R. R., Miller, N. J., Annamalai, L., Berry, S., Chartash, E. K., Daud, A., Fling, S. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603702 · Cited by 1,258
Cited by
Items 501–600 of 1,006
Lü, H., Liang, Y., Guan, B., Shi, Y. X., Gong, Y., Li, J., Kong, W., Liu, J., Fang, D., Liu, L., et al. (2020) · Theranostics · doi:10.7150/thno.43251 · Cited by 70
“The AA Sig subtype bears high mutation burdens and thus may be a good candidate for immune checkpoint blockade therapy [19].”
BackgroundMetastatic Urothelial Cancer: a rapidly changing treatment landscape
Stecca, C., Abdeljalil, O., & Sridhar, S. S. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211047352 · Cited by 69
Vaddepally, R. K., Doddamani, R., Sodavarapu, S., Madam, N. R., Katkar, R. B., Kutadi, A. P., Mathew, N., Garje, R., & Chandra, A. B. (2022) · Biomedicines · doi:10.3390/biomedicines10040790 · Cited by 71
“Incidence of pneumonitis for PD-1/PD-L1 inhibitor monotherapy versus combination therapy with CTLA-4 inhibitor was 3% and 10%, respectively [5,6,48].”
BackgroundMethodHuang, K., Lin, B., Liu, J., Liu, Y., Li, J., Tian, G., & Yang, J. (2022) · Bioinformatics · doi:10.1093/bioinformatics/btac641 · Cited by 67
Dai, S., Chen, Y., Cai, W., Dong, S., Zhao, J., Chen, L., & Cheng, C. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01739-6 · Cited by 74
“Other studies with small HCC samples (N 50) also support the low TMB ( 6 mutations/Mb) condition at the median level [175, 176].”
Epigenetic landscape of small cell lung cancer: small image of a giant recalcitrant disease
Κhan, P., Siddiqui, J. A., Maurya, S. K., Lakshmanan, I., Jain, M., Ganti, A. K., Salgia, R., Batra, S. K., & Nasser, M. W. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.11.006 · Cited by 69
Mutation–selection balance and compensatory mechanisms in tumour evolution
Persi, E., Wolf, Y. I., Horn, D., Ruppin, E., Demichelis, F., Gatenby, R. A., Gillies, R. J., & Koonin, E. V. (2020) · Nature Reviews Genetics · doi:10.1038/s41576-020-00299-4 · Cited by 68
Bossi, P., Alfieri, S., Strojan, P., Takes, R. P., López, F., Mäkitie, A. A., Saba, N. F., Rodrigo, J. P., Bradford, C. R., Suarez, C. M., et al. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.01.018 · Cited by 64
“In general, we have learned that higher TMB is correlated to higher probability of response to PD-1/PD-L1 axis inhibition (Yarchoan et al., 2017).”
BackgroundSena, L. A., Fountain, J., Velho, P. I., Lim, S. J., Wang, H., Nizialek, E. A., Rathi, N., Nussenzveig, R. H., Maughan, B. L., Vélez, M. G., et al. (2020) · The Oncologist · doi:10.1002/onco.13601 · Cited by 65
m 6 A modification patterns and tumor immune landscape in clear cell renal carcinoma
Zhong, J., Liu, Z., Cai, C., Duan, X., Deng, T., & Zeng, G. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001646 · Cited by 83
Wang, W., Yuan, T., Ma, L., Zhu, Y., Bao, J., Zhao, X., Zhao, Y., Zong, Y., Zhang, Y., Yang, S., et al. (2022) · Advanced Science · doi:10.1002/advs.202105810 · Cited by 78
Peiffer, L. B., White, J. R., Jones, C. B., Slottke, R., Ernst, S. E., Moran, A. E., Graff, J. N., & Sfanos, K. S. (2022) · Neoplasia · doi:10.1016/j.neo.2022.100822 · Cited by 63
Biomarkers for response to TIL therapy: a comprehensive review
Albarrán, V., Martinez, P. B., Granhøj, J. S., Borch, T. H., Donia, M., & Svane, I. M. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008640 · Cited by 72
“3 26 27 In a phase I/II trial with TIL-ACT before the anti- PD-1 era, a higher TMB was correlated with longer progression-free survival (PFS) and overall survival (OS) in 27 patients with MM. 28 Later, Levi et al 29 reported higher TMB in responders both among anti- PD- 1-naïve and -exposed…”
BackgroundKaderbhaï, C., Tharin, Z., & Ghiringhelli, F. (2019) · Cancers · doi:10.3390/cancers11020201 · Cited by 69
“found a correlation between TMB and objective response rates to immunotherapy in a cohort, including 27 different tumor types [32].”
BackgroundThe Beneficial Role of Sunitinib in Tumor Immune Surveillance by Regulating Tumor PD‐L1
Li, H., Kuang, X., Liang, L., Ye, Y., Zhang, Y., Li, J., Ma, F., Tao, J., Lei, G., Zhao, S., et al. (2020) · Advanced Science · doi:10.1002/advs.202001596 · Cited by 69
Shimada, Y., Okuda, S., Watanabe, Y., Tajima, Y., Nagahashi, M., Ichikawa, H., Nakano, M., Sakata, J., Takii, Y., Kawasaki, T., et al. (2021) · Journal of Gastroenterology · doi:10.1007/s00535-021-01789-w · Cited by 67
“Tumor mutational burden-high (TMB-H), which is detected with gene panel testing, is a promising biomarker for ICIs in many solid cancers [3–7].”
BackgroundAdvances in Small-Cell Lung Cancer (SCLC) Translational Research
Drapkin, B. J., & Rudin, C. M. (2020) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a038240 · Cited by 68
Pestinger, V., Smith, M. R., Sillo, T., Findlay, J. M., Laes, J., Martin, G., Middleton, G., Taniere, P., & Beggs, A. D. (2020) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-020-00462-x · Cited by 63
Jain, A., & Bhardwaj, V. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i39.6527 · Cited by 75
Zhou, K., Cao, J., Lin, H., Liang, L., Shen, Z., Wang, L., Peng, Z., & Mei, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.962173 · Cited by 67
“Furthermore, high PLR was significantly associated with poor OS and PFS in advanced non-small cell lung cancer frontiersin.org01 Abbreviations: PLR, platelet-to-lymphocyte ratio; N lung cancer; SCLC, small cell lung cancer; OS, HR, h ratio; CI, confidence interval; PFS, progression-free survival; ORR, objective respon…”
BackgroundRNA vaccines for cancer: Principles to practice
Guasp, P., Reiche, C., Sethna, Z. M., & Balachandran, V. P. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.05.005 · Cited by 69
Stepanenko, A. A., & Chekhonin, V. P. (2018) · Cancers · doi:10.3390/cancers10120492 · Cited by 65
“The authors observed a strong correlation between them, with glioma/glioblastoma predicted to be among tumor types with the lowest chances to respond [138].”
BackgroundWang, H., Milberg, O., Bartelink, I. H., Vicini, P., Wang, B., Narwal, R., Roskos, L., Santa-Maria, C. A., & Popel, A. S. (2019) · Royal Society Open Science · doi:10.1098/rsos.190366 · Cited by 60
Simonaggio, A., Elaidi, R., Fournier, L. S., Fabre, E., Ferrari, V., Borchiellini, D., Thouvenin, J., Barthélémy, P., Thibault, C., Tartour, É., et al. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02637-1 · Cited by 70
Saxena, K., Herbrich, S. M., Pemmaraju, N., Kadia, T. M., Dinardo, C. D., Borthakur, G. M., Pierce, S. A., Jabbour, E. J., Wang, S. A., Bueso-Ramos, C., et al. (2021) · Cancer · doi:10.1002/cncr.33690 · Cited by 65
“16 ICI efficacy typically correlates with the tumor mutational burden.(17) The tumor mutational burden of AML is logarithmically lower compared with that of many solid tumor malignancies.”
BackgroundEckert, F., Zwirner, K., Boeke, S., Thorwarth, D., Zips, D., & Huber, S. M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00407 · Cited by 62
“Intriguingly, mutational burden is one of the most promising predictive factor for treatment with immune-checkpointinhibition (107).”
BackgroundTargeting Immune-Related Biological Processes in Solid Tumors: We do Need Biomarkers
Pagni, F., Guerini‐Rocco, E., Schultheis, A. M., Grazia, G., Rijavec, E., Ghidini, M., Lopez, G., Venetis, K., Croci, G. A., Malapelle, U., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215452 · Cited by 64
Krieger, T., Pearson, I. V., Bell, J. A., Doherty, J. P., & Robbins, P. B. (2020) · Diagnostic Pathology · doi:10.1186/s13000-020-0927-9 · Cited by 63
The therapeutic landscape of hepatocellular carcinoma
Gallage, S., Beccaria, M. G., Szydlowska, M., Rahbari, M., Mohr, R. U., Tacke, F., & Heikenwälder, M. F. (2021) · Med · doi:10.1016/j.medj.2021.03.002 · Cited by 64
Immunotherapy-related biomarkers: Confirmations and uncertainties
Catalano, M., Iannone, L. F., Nesi, G., Nobili, S., Mini, E., & Roviello, G. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104135 · Cited by 71
Williams, H. L., Frei, A. L., Koessler, T., Berger, M. D., Dawson, H., Michielin, O. A., & Zlobec, I. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00671-1 · Cited by 77
Ballotti, R., Chéli, Y., & Bertolotto, C. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01290-7 · Cited by 67
“The higher the mutational burden is, the better the response to immune checkpoint inhibitors [50].”
BackgroundGenetic Differences Between Bladder and Upper Urinary Tract Carcinoma: Implications for Therapy
Sfakianos, J. P., Gul, Z., Shariat, S. F., Matin, S. F., Daneshmand, S., Plimack, E. R., Lerner, S. P., Morgan Rouprêt, A., & Pal, S. K. (2020) · European Urology Oncology · doi:10.1016/j.euo.2020.12.007 · Cited by 65
Pilot study of bempegaldesleukin in combination with nivolumab in patients with metastatic sarcoma
D’Angelo, S. P., Richards, A. L., Conley, A. P., Woo, H. J., Dickson, M. A., Gounder, M., Kelly, C., Keohan, M. L., Movva, S., Thornton, K., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30874-8 · Cited by 60
Cancer Immunosurveillance by T Cells
(2019) · International Review of Cell and Molecular Biology · doi:10.1016/bs.ircmb.2018.08.001 · Cited by 58
Contemporary Treatment of Locally Advanced Oral Cancer
Kim, D. S., & Li, R. T. (2019) · Current Treatment Options in Oncology · doi:10.1007/s11864-019-0631-8 · Cited by 64
The Crossroads of Cancer Epigenetics and Immune Checkpoint Therapy
Micevic, G., Bosenberg, M., & Yan, Q. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-0784 · Cited by 63
Madeddu, C., Busquets, S., Donisi, C., Lai, E., Pretta, A., López-Soriano, F. J., Argilés, J. M. A., Scartozzi, M., & Macciò, A. (2023) · Cancers · doi:10.3390/cancers15041076 · Cited by 70
Radioimmunotherapy in colorectal cancer treatment: present and future
Shi, J., Sun, Z., Gao, Z., Huang, D., Hong, H., & Gu, J. F. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1105180 · Cited by 67
“Patients with high TMB have demonstrated good responses to anti-PD-1 therapy because TMB is associated with a high frequency of new antigens (63).”
BackgroundMenard, L. C., Fischer, P. A., Kakrecha, B., Linsley, P. S., Wambre, E. R., Liu, M. C., Rust, B. J., Lee, D., Penhallow, B. A., Manjarrez‐Orduño, N., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02728 · Cited by 65
“To effectively reject tumor cells, immunogenic antigens have to be generated (5, 6) and accessible to antigen-specific T cells, which need to infiltrate the tumor.”
BackgroundGardner, A., Pulido, Á. D. M., Hänggi, K., Bazargan, S., Onimus, A., Kasprzak, A., Conejo-Garcia, J. R., Rejniak, K. A., & Ruffell, B. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003571 · Cited by 62
Karamitopoulou, E., Andreou, A., Wenning, A. S., Gloor, B., & Perren, A. A. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.03.033 · Cited by 65
Widespread hypertranscription in aggressive human cancers
Zatzman, M., Fuligni, F., Ripsman, R., Suwal, T., Comitani, F., Edward, L.-M., Denroche, R. E., Jang, G. H., Notta, F., Gallinger, S., et al. (2022) · Science Advances · doi:10.1126/sciadv.abn0238 · Cited by 72
“other (23) +++++++++ +++ + + + + ++++++ +++ + +++”
BackgroundPrognostic Factors for Checkpoint Inhibitor Based Immunotherapy: An Update With New Evidences
Yan, X., Zhang, S., Deng, Y., Wang, P., Hou, Q., & Xu, H. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01050 · Cited by 57
Nejo, T., Yamamichi, A., Almeida, N. D., Goretsky, Y. E., & Okada, H. (2020) · Seminars in Immunology · doi:10.1016/j.smim.2020.101385 · Cited by 64
Leiter, U., Loquai, C., Reinhardt, L., Rafei-Shamsabadi, D. A., Gutzmer, R., Kaehler, K. C., Heinzerling, L., Hassel, J. C., Glutsch, V., Sirokay, J. D., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000897 · Cited by 62
Precision Medicine Approaches to Overcome Resistance to Therapy in Head and Neck Cancers
Ortiz‐Cuaran, S., Bouaoud, J., Karabajakian, A., Fayette, J., & Saintigny, P. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.614332 · Cited by 65
Fabian, K. P., Padget, M. R., Fujii, R., Schlom, J., & Hodge, J. W. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001691 · Cited by 59
Hoefflin, R., Lazarou, A., Hess, M. E., Reiser, M., Wehrle, J., Metzger, P., Frey, A. V., Becker, H., Aumann, K., Berner, K., et al. (2021) · Cancers · doi:10.3390/cancers13051151 · Cited by 61
Therapeutic applications of the cancer immunoediting hypothesis
Desai, R. R., Coxon, A. T., & Dunn, G. P. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.03.002 · Cited by 59
Efficacy of Immune Checkpoint Inhibitors in SMARCA4-Deficient Thoracic Tumor
Shinno, Y., Yoshida, A., Masuda, K., Matsumoto, Y., Okuma, Y., Yoshida, T., Goto, Y., Horinouchi, H., Yamamoto, N., Yatabe, Y., et al. (2022) · Clinical Lung Cancer · doi:10.1016/j.cllc.2022.03.005 · Cited by 61
From rough to precise: PD-L1 evaluation for predicting the efficacy of PD-1/PD-L1 blockades
Zhao, X., Bao, Y., Meng, B., Xu, Z., Li, S., Wang, X., Hou, R., Ma, W., Liu, D., Zheng, J., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.920021 · Cited by 67
“The immune checkpoint inhibitors (ICIs) targeting PD-1 and PD-L1, which have improved the outcomes of patients with various forms of advance-stage tumor, mark a landmark breakthrough in cancer treatment (1).”
BackgroundTumor-derived erythropoietin acts as an immunosuppressive switch in cancer immunity
Chiu, D. K., Zhang, X., Cheng, B. Y.-L., Liu, Q., Hayashi, K., Yu, B., Lee, R. C., Zhang, C. R., An, X., Rajadas, J., et al. (2025) · Science · doi:10.1126/science.adr3026 · Cited by 62
First-Line Therapies for Metastatic Lung Adenocarcinoma Without a Driver Mutation
Bodor, J. N., Kasireddy, V., & Borghaei, H. (2018) · Journal of Oncology Practice · doi:10.1200/jop.18.00250 · Cited by 66
Personal Mutanomes Meet Modern Oncology Drug Discovery and Precision Health
Cheng, F., Liang, H., Butte, A. J., Eng, C., & Nussinov, R. (2018) · Pharmacological Reviews · doi:10.1124/pr.118.016253 · Cited by 61
“A recent study examined the relationship between the objective response rate for anti-PD-1/anti-PD-L1 therapy and the corresponding median tumor mutational burden across 27 cancer types/subtypes (Yarchoan et al., 2017).”
BackgroundImmune checkpoint inhibitors in advanced or metastatic mucosal melanoma: a systematic review
Li, J., Kan, H., Zhao, L., Sun, Z., & Bai, C. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920922028 · Cited by 62
Bohaumilitzky, L., Kluck, K., Hüneburg, R., Gallon, R., Nattermann, J., Kirchner, M., Kristiansen, G., Hommerding, O., Pfuderer, P. L., Wagner, L., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.11.029 · Cited by 62
Loss of Rnf31 and Vps4b sensitizes pancreatic cancer to T cell-mediated killing
Frey, N., Tortola, L., Egli, D., Janjuha, S., Rothgangl, T., Marquart, K. F., Ampenberger, F., Köpf, M., & Schwank, G. (2022) · Nature Communications · doi:10.1038/s41467-022-29412-3 · Cited by 59
CD39 – A bright target for cancer immunotherapy
Guo, S., Han, F., & Zhu, W. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113066 · Cited by 61
Aria, H., & Rezaei, M. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114503 · Cited by 59
Wang, D., Wu, S., He, J., Sun, L., Zhu, H., Zhang, Y., Liu, S., Duan, X., Wang, Y., & Xu, T. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02758-2 · Cited by 62
“Immune checkpoint blockade (ICB) therapies have shown to be effective in metastatic melanoma and nonsmall cell lung cancer [18, 19], and clinical trials in cervical cancer and other cancers are currently underway [20], however drug resistance and recurrence remain common [21].”
BackgroundTorres, E. T. R., Ho, W. J., Danilova, L., Tandurella, J. A., Leatherman, J. M., Rafie, C. I., Wang, C., Brufsky, A., LoRusso, P. M., Chung, V. M., et al. (2024) · Nature Cancer · doi:10.1038/s43018-024-00729-w · Cited by 66
“Similarly, a TMB of ≥10 mutations per Mb at baseline is used as a predictive biomarker for response to ICIs in various tumor types 47–49 , however most often not in individuals with breast cancer 50 .”
Self-citationGiannini, E. G., Aglitti, A., Borzio, M., Gambato, M., Guarino, M., Iavarone, M. A., Lai, Q., Sandri, G. B. L., Melandro, F., Morisco, F., et al. (2019) · Cancers · doi:10.3390/cancers11111689 · Cited by 63
“Conversely, tumours with lower mutational burden present less immunogenic antigens and lower immune infiltration and, therefore, they are better candidates to other therapies [43,44].”
BackgroundKroeze, L. I., de Voer, R. M., Kamping, E. J., von Rhein, D. T., Jansen, E. A. M., Hermsen, M. J. W., Barberis, M. C. P., Botling, J., Garrido-Martin, E. M., Haller, F., et al. (2020) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2020.02.009 · Cited by 58
Wang, K., Patkar, S., Lee, J. S., Gertz, E. M., Robinson, W., Schischlik, F., Crawford, D. R., Schäffer, A. A., & Ruppin, E. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0887 · Cited by 55
Cell Fate Reprogramming in the Era of Cancer Immunotherapy
Zimmermannova, O., Caiado, I., Ferreira, A. G., & Pereira, C.-F. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.714822 · Cited by 56
Gao, C., Li, H., Liu, C., Xu, X., Zhuang, J., Zhou, C., Liu, L., Feng, F., & Sun, C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.650491 · Cited by 61
“Studies have shown that the mutation load or the number of mutations in tumor DNA is an adequate marker for predicting the response of checkpoint inhibitor immunotherapy to different cancers (10, 11).”
BackgroundGorchs, L., & Kaipe, H. (2021) · Cancers · doi:10.3390/cancers13122995 · Cited by 64
Combinational blockade of MET and PD-L1 improves pancreatic cancer immunotherapeutic efficacy
Li, E., Huang, X., Zhang, G., & Liang, T. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02055-w · Cited by 61
Lonardi, S., Prete, A. A., Morano, F., Messina, M., Formica, V., Corsi, D. C., Orciuolo, C., Frassineti, G. L., Zampino, M. G., Casagrande, M., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002996 · Cited by 59
Immune checkpoint inhibitors for the treatment of melanoma
Sabbatino, F., Liguori, L., Pepe, S., & Ferrone, S. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2038132 · Cited by 61
Neoadjuvant immunotherapy for resectable esophageal cancer: A review
Li, Q., Liu, T., & Ding, Z. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1051841 · Cited by 57
Tsai, Y.-T., Schlom, J., & Donahue, R. N. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-02969-1 · Cited by 69
“TMB is a tissue-based biomarker that has been extensively explored to predict clinical outcomes of cancer patients to ICI [16].”
BackgroundPu, X., Wu, L., Su, D., Mao, W., & Fang, B. (2018) · BMC Cancer · doi:10.1186/s12885-018-4990-5 · Cited by 58
Nivolumab Plus Ipilimumab in Non-Small-Cell Lung Cancer
Reck, M., Borghaei, H., & O'Byrne, K. J. (2019) · Future Oncology · doi:10.2217/fon-2019-0031 · Cited by 58
Berghoff, A. S., Bellosillo, B., Caux, C., Langen, A. J. D., Mazières, J., Normanno, N., Preusser, M., Provencio, M., Rojo, F., Wolf, J., et al. (2019) · ESMO Open · doi:10.1136/esmoopen-2019-000498 · Cited by 58
Chang, H., Sasson, A., Srinivasan, S., Golhar, R., Greenawalt, D. M., Geese, W. J., Green, G., Zerba, K., Kirov, S., & Szustakowski, J. (2019) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-019-00408-y · Cited by 54
“12 into TMB tertiles based on their WES-derived somatic missense mutations (low [0–100], medium [100–242], high [≥243]).”
BackgroundChoosing tumor mutational burden wisely for immunotherapy: A hard road to explore
Li, R., Han, D., Shi, J., Han, Y., Tan, P., Zhang, R., & Li, J. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188420 · Cited by 67
Nerurkar, S. N., Goh, D. L. M., Cheung, C. C. L., Nga, P. Q. Y., Lim, J. C. T., & Yeong, J. P.-S. (2020) · Cancers · doi:10.3390/cancers12092572 · Cited by 60
EPHA7 mutation as a predictive biomarker for immune checkpoint inhibitors in multiple cancers
Zhang, Z., Wu, H., Lin, W., Wang, Z., Yang, L.-P., Zeng, Z.-L., & Luo, H. (2021) · BMC Medicine · doi:10.1186/s12916-020-01899-x · Cited by 63
“TMB was defined as the total number of nonsynonymous somatic, coding, base substitution, and indel mutations per megabase (Mb) of genome examined [33].”
BackgroundLong, J., Wang, D., Wang, A., Chen, P., Lin, Y. S., Bian, J., Yang, X., Zheng, M., Zhang, H., Zheng, Y., et al. (2022) · Genome Medicine · doi:10.1186/s13073-022-01024-y · Cited by 63
“This may be due to the higher response rate of renal cell carcinoma and melanoma than other tumors to immunotherapy [68].”
BackgroundThe advanced development of molecular targeted therapy for hepatocellular carcinoma
Yan, T., Yu, L., Zhang, N., Peng, C., Su, G., Jing, Y., Zhang, L., Wu, T., Cheng, J., Guo, Q., et al. (2022) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2021.0661 · Cited by 63
Combined Hepatocellular-Cholangiocarcinoma: Biology, Diagnosis, and Management
Ye, L., Schneider, J. S., Khaled, N. B., Schirmacher, P., Seifert, C., Frey, L., He, Y., Geier, A., Toni, E. N. D., Zhang, C., et al. (2023) · Liver Cancer · doi:10.1159/000530700 · Cited by 61
“Furthermore, immunotherapy may be applied to patients with a microsatellite instability-high (MSI-H) status [23] or with a high mutational burden [123], which may be considered in polymerase epsilon-mutated tumors [124] because of the tumor-agnostic ef fi cacy of immunotherapy in such cases.”
BackgroundMina, D. S., Au, D., Brunet, J., Jones, J. M., TOMLINSON, G. A., Taback, N., Field, D., Berlingeri, A., Bradley, H., & Howell, D. (2017) · Current Oncology · doi:10.3747/co.23.3585 · Cited by 58
Xu, J., Saklatvala, R., Mittal, S., Deshmukh, S., & Procopio, A. (2020) · Advanced Science · doi:10.1002/advs.201903394 · Cited by 56
Tamura, R., Yoshihara, K., Nakaoka, H., Yachida, N., Yamaguchi, M., Suda, K., Ishiguro, T., Nishino, K., Ichikawa, H., Homma, K., et al. (2020) · Oncogene · doi:10.1038/s41388-020-1237-0 · Cited by 57
Predictive Biomarkers of Immune Checkpoint Inhibition in Gastroesophageal Cancers
Sundar, R., Smyth, E. C., Peng, S., Yeong, J. P.-S., & Tan, P. B. O. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00763 · Cited by 57
High tumor mutation burden is associated with DNA damage repair gene mutation in breast carcinomas
Mei, P., Freitag, C. E., Wei, L., Zhang, Y., Parwani, A. V., & Li, Z. (2020) · Diagnostic Pathology · doi:10.1186/s13000-020-00971-7 · Cited by 59
Lin, A., Zhang, H., Hu, X., Chen, X., Wu, G., Luo, P., & Zhang, J. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105028 · Cited by 62
Kuipers, H., de Bitter, T. J. J., de Boer, M. T., van der Post, R. S., Nijkamp, M. W., de Reuver, P. R., Fehrmann, R. S. N., & Hoogwater, F. J. H. (2021) · Cancers · doi:10.3390/cancers13215257 · Cited by 57
Ma, R., Rei, M., Woodhouse, I. B., Ferris, K., Kirschner, S. A., Chandran, A., Gileadi, U., Chen, J., Pinho, M. P., Ariosa-Morejon, Y., et al. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac107 · Cited by 69
“17,18 The low TMB seen in GBM, 19,20 as well as its’ immunosuppressive microenvironment with infiltration of microglia, myeloid-derived suppressor cells, high levels of CCL2, CXCL2, and TGF-ß 21 help to explain the poor response rate to such immunotherapies.”
Gu, X., Guan, J., Xu, J. X., Zheng, Q., Chen, C., Yang, Q., Huang, C., Wang, G., Zhou, H., Chen, Z., et al. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-020-02691-4 · Cited by 61
“TMB is an emerging biomarker of sensitivity to immunotherapy [39, 40].”
BackgroundTunali, I., Tan, Y. Q., Gray, J. E., Katsoulakis, E., Eschrich, S. A., Saller, J. J., Aerts, H. J. W. L., Boyle, T. A., Qi, J., Güveniş, A., et al. (2021) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkab048 · Cited by 55
A framework for fibrolamellar carcinoma research and clinical trials
Dinh, T. A., Utria, A. F., Barry, K. C., Ma, R. K., Abou‐Alfa, G. K., Gordan, J. D., Jaffee, E. M., Scott, J. D., Zucman‐Rossi, J., O'Neill, A. F., et al. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00580-3 · Cited by 60
“This finding is often attributed to the random generation of large numbers of neoantigens that could be targeted by the immune system 110 .”
BackgroundSelf-citationThe Role of ctDNA in Gastric Cancer
Mencel, J., Slater, S., Cartwright, E., & Starling, N. (2022) · Cancers · doi:10.3390/cancers14205105 · Cited by 58
“High tissue-based TMB (tTMB) scores are associated with higher response rates to antiPD1 therapies, which is a tendency seen across several tumour types including GC [69,70].”
BackgroundPrecision Medicine in Bladder Cancer: Present Challenges and Future Directions
Mohanty, S. K., Lobo, A., Mishra, S. K., & Cheng, L. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13050756 · Cited by 56
Impact of curative radiotherapy on the immune status of patients with localized prostate cancer
Eckert, F., Schaedle, P., Zips, D., Schmid-Horch, B. D., Rammensee, H., Gani, C., & Gouttefangeas, C. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1496881 · Cited by 55
“Checkpoint inhibitors have shown limited efficacy so far, which might be related to the low mutational load in this tumor.(24,25) A randomized phase III”
BackgroundTuccitto, A., Shahaj, E., Vergani, E., Ferro, S., Huber, V., Rodolfo, M., Castelli, C., Rivoltini, L., & Vallacchi, V. (2018) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-018-2477-z · Cited by 56
“Notably, a correlation between TMB, as the number of coding mutations per megabase (Mb), and the objective response rate to anti PD-1 and PD-L1 therapy has been reportedwhen the data from 27 tumor types were analyzed [24].”
BackgroundStein, M. K., Pandey, M. K., Xiu, J., Tae, H., Swensen, J. J., Mittal, S., Brenner, A. J., Korn, W. M., Heimberger, A. B., & Martin, M. G. (2019) · JCO Precision Oncology · doi:10.1200/po.18.00376 · Cited by 59
Impact of Tumor and Immunological Heterogeneity on the Anti-Cancer Immune Response
Shembrey, C., Huntington, N. D., & Hollande, F. (2019) · Cancers · doi:10.3390/cancers11091217 · Cited by 56
“Whilst clinical responses to immune checkpoint blockade in cancer types with traditionally low TMB have been reported, these are generally restricted to virally-induced cancers, such as Merkel cell carcinoma and human papilloma virus-positive head and neck squamous cell carcinoma (HPV+ HNSCC), which show enhanced T-ce…”
Background
Metadata
- Authors
- Yarchoan, M., Hopkins, A., & Jaffee, E. M.
- Affiliations
- Johns Hopkins University (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-12-21
- Volume
- 377
- Issue
- 25
- Pages
- 2500-2501
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC6549688
- OpenAlex
- W2779221466
- Cited by
- 3,230
- References
- 5
- Citations by year
- 2026: 181 · 2025: 274 · 2024: 410 · 2023: 460 · 2022: 525 · 2021: 558 · 2020: 408 · 2019: 255 · 2018: 153 · 2017: 1
- FWCI
- 98.33
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (P30CA006973)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- tumor mutational burden, anti-PD-1 therapy, PD-L1 blockade, immune checkpoint inhibitors, cancer immunotherapy response, predictive biomarkers, cancer types
- MeSH terms
- Antineoplastic Agents, DNA Mutational Analysis, Humans, Models, Genetic, Mutation, Neoplasms, Biomarkers, Tumor, B7-H1 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.